These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32394430)

  • 21. Ethical Considerations for Pediatric Placebo-Controlled Trials: FDA Outcomes and Perspectives.
    Momper JD; Green DJ; Park K; Burckart GJ; Snyder DL
    Ther Innov Regul Sci; 2021 Mar; 55(2):282-303. PubMed ID: 32901443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
    Ostroff C; Lee CE; McMeekin J
    Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers.
    Hwang TJ; Orenstein L; DuBois SG; Janeway KA; Bourgeois FT
    J Natl Cancer Inst; 2020 Mar; 112(3):224-228. PubMed ID: 31665394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012.
    Sinha MS; Najafzadeh M; Rajasingh EK; Love J; Kesselheim AS
    JAMA Intern Med; 2018 Nov; 178(11):1458-1466. PubMed ID: 30264138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IOM Review of FDA--approved biologics labeled or studied for pediatric use.
    Field MJ; Ellinger LK; Boat TF
    Pediatrics; 2013 Feb; 131(2):328-35. PubMed ID: 23319521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
    Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
    Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.
    Poon R; Khanijow K; Umarjee S; Fadiran E; Yu M; Zhang L; Parekh A
    J Womens Health (Larchmt); 2013 Jul; 22(7):604-16. PubMed ID: 23768021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.
    Kim T; Han N; Sohn M; Oh JM; Lee EK; Ji E; Kim IW
    Basic Clin Pharmacol Toxicol; 2015 May; 116(5):438-44. PubMed ID: 25348905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal Antibodies and Fc-Fusion Proteins for Pediatric Use: Dosing, Immunogenicity, and Modeling and Simulation in Data Submitted to the US Food and Drug Administration.
    Liu XI; Dallmann A; Wang YM; Green DJ; Burnham JM; Chiang B; Wu P; Sheng M; Lu K; van den Anker JN; Burckart GJ
    J Clin Pharmacol; 2019 Aug; 59(8):1130-1143. PubMed ID: 30865317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Food-Drug Effects and Pediatric Drug Development Studies Submitted to the US Food and Drug Administration, 2012-2022.
    Tunehag KR; George B; Samuels S; Vo K; Arya V; Abulwerdi G; Burckart GJ
    J Clin Pharmacol; 2024 Jun; 64(6):697-703. PubMed ID: 38294346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration.
    Hong YD; Villalonga-Olives E; Perfetto EM
    Value Health; 2019 Aug; 22(8):925-930. PubMed ID: 31426934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaceuticals and Medical Devices: FDA Oversight.
    White RS;
    Issue Brief Health Policy Track Serv; 2017 Dec; 2017():1-43. PubMed ID: 29361661
    [No Abstract]   [Full Text] [Related]  

  • 35. Pediatric Drug Development: Outlook for Science-Based Innovation.
    Green DJ; Zineh I; Burckart GJ
    Clin Pharmacol Ther; 2018 Mar; 103(3):376-378. PubMed ID: 29384202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and Drug Administration for Pediatric Approval.
    Zimmerman K; Putera M; Hornik CP; Brian Smith P; Benjamin DK; Mulugeta Y; Burckart GJ; Cohen-Wolkowiez M; Gonzalez D
    Clin Ther; 2016 Sep; 38(9):1995-2005. PubMed ID: 27364807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comparison of Pediatric and Adult Safety Studies for Antipsychotic and Antidepressant Drugs Submitted to the United States Food and Drug Administration.
    Liu XI; Schuette P; Burckart GJ; Green DJ; La J; Burnham JM; Rakhmanina N; Robb A; Huang SM; van den Anker JN
    J Pediatr; 2019 May; 208():236-242.e3. PubMed ID: 30679050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The National Institutes of Health and the Best Pharmaceuticals for Children Act.
    Zajicek A
    Paediatr Drugs; 2009; 11(1):45-7. PubMed ID: 19127953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs.
    Ladanie A; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    Trials; 2018 Sep; 19(1):505. PubMed ID: 30231912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.
    Rivera DR; Hartzema AG
    Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.